No Data
Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13
Express News | Capricor Therapeutics Files Prospectus Relates to Resale by Selling Stockholder of up to 2.8 Mln Shares of Common Stock -SEC Filing
Capricor Therapeutics Analyst Ratings
Retail Investors Account for 45% of Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Ownership, While Institutions Account for 14%
Piper Sandler Initiates Capricor Therapeutics(CAPR.US) With Buy Rating, Announces Target Price $35
Buy Rating for Capricor Therapeutics: Promising Deramiocel Development and Strategic Partnerships
No Data
No Data